
    
      XP and SP are either standard treatment for advanced gastric cancer. The aim of this study is
      to elucidate the efficacy and safety of Capecitabine/Cisplatin and S-1/Cisplatin for
      first-line treatment of Advanced Gastric Cancer.
    
  